Compare GoPro Inc (GPRO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Viatris Inc — how do they compare? GoPro Inc trades at $0.58 (market cap $114.41M), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 163.4× GoPro Inc's market cap, and Viatris Inc pays a 2.95% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | VTRS | |
|---|---|---|
Market Cap | $114.41M | $18.69B |
Sector | Technology | Health |
52-Week High | $2.88 | $17.86 |
52-Week Low | $0.62 | $9.49 |
Enterprise Value | $173.19M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.58, down 17.87% amid ongoing financial challenges. The company reported Q2 2026 revenue of $105 million with negative earnings, continuing a trend of revenue decline from $1.1B in 2022 to $652M in 2025. Technical indicators show bearish momentum with RSI at oversold levels, while fundamentals reveal negative net income margins and cash flow concerns despite low valuation multiples.
The outlook remains highly speculative with a strategic sale process underway. Investment opportunity exists only for event-driven speculators betting on acquisition potential, while significant risks include going concern warnings, persistent cash burn, and competitive pressures in the action camera market.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
